Rigel (RIGL)
NASDAQ:RIGL
Want to see RIGL full AI Analyst Report?
RIGL Stock Chart & Stats
$32.43
-$0.99(-5.79%)
At close: 4:00 PM EST
$32.43
-$0.99(-5.79%)
Day’s Range― - ―
52-Week Range$16.88 - $52.24
Previous CloseN/A
Volume99.93K
Average Volume (3M)342.08K
Market Cap
$543.31M
Enterprise Value$558.62M
Total Cash (Recent Filing)$154.96M
Total Debt (Recent Filing)$53.30M
Price to Earnings (P/E)2.1
Beta1.94
Next Earnings
May 05, 2026EPS Estimate
0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)20.24
Shares Outstanding18,480,019
10 Day Avg. Volume412,362
30 Day Avg. Volume342,078
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.97
Price to Sales (P/S)2.62
P/FCF Ratio10.18
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue1.90
Enterprise Value/Gross Profit2.03
Enterprise Value/Ebitda4.37
Forecast
1Y Price Target
$51.50Price Target Upside58.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)4.35
Revenue Forecast (FY)$284.13M
Bulls Say, Bears Say
Bulls Say
Clinical DataDurable clinical benefit for Gavreto and higher observed overall survival in U.S. patients support a potential U.S. commercial advantage versus competing RET inhibitors.
Earlier‑line AdoptionStronger survival in treatment‑naïve patients supports use of Gavreto in earlier treatment lines, potentially expanding the addressable market and boosting uptake.
Pipeline ProgressionAdvancement of R289 into dose expansion with planned dose selection and an FDA meeting, alongside initiation of a Phase 2 study in IDH1‑mutant high‑grade glioma, supports ongoing pipeline progression toward registrational goals.
Bears Say
Clinical And Funding RiskFailed or inconclusive clinical trials or inability to secure adequate funding could prevent the stock from reaching the analyst's price target.
Earnings QualityReported earnings were boosted by a large non‑cash deferred tax benefit, creating a notable gap versus operational expectations and raising questions about earnings sustainability.
Tax Accounting ImpactRecording federal and state income tax expenses through the income statement each quarter is expected to reduce accounting net income and earnings per share, increasing volatility in reported results.
Rigel News
RIGL FAQ
What was Rigel’s price range in the past 12 months?
Rigel lowest stock price was $16.88 and its highest was $52.24 in the past 12 months.
What is Rigel’s market cap?
Rigel’s market cap is $543.31M.
When is Rigel’s upcoming earnings report date?
Rigel’s upcoming earnings report date is May 05, 2026 which is today.
How were Rigel’s earnings last quarter?
Currently, no data Available
Is Rigel overvalued?
According to Wall Street analysts Rigel’s price is currently Undervalued.
Does Rigel pay dividends?
Rigel does not currently pay dividends.
What is Rigel’s EPS estimate?
Rigel’s EPS estimate is 0.8.
How many shares outstanding does Rigel have?
Rigel has 18,480,019 shares outstanding.
What happened to Rigel’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rigel?
Currently, no hedge funds are holding shares in RIGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rigel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$51.50 (58.80% Upside)
$51.50 (58.80% Upside)
Blogger Sentiment
Bullish
RIGL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 97.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $145.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
92.46%
12-Months-Change
Fundamentals
Return on Equity
240.83%
Trailing 12-Months
Asset Growth
13.67%
Trailing 12-Months
Company Description
Rigel
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
RIGL Company Deck
RIGL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial progress: materially higher net product sales (232M, +60% YoY), strong Q4 growth (+41% YoY), profitable operations and a doubled cash position, alongside encouraging early clinical data for R289 with regulatory designations. However, several important caveats were emphasized: a large portion of reported GAAP net income resulted from a noncash deferred tax benefit, parts of 2025 growth were aided by one-time affordability and gross-to-net effects, and R289 efficacy data remain from a small, heavily pretreated cohort requiring confirmatory data. Management set conservative yet growth-positive 2026 guidance and outlined disciplined BD and clinical milestones. Balancing robust commercial momentum and promising early clinical signals versus accounting-driven income effects, one-time drivers, and clinical/BD execution risks, the overall tone is optimistic with measured caution.View all RIGL earnings summariesRIGL Stock 12 Month Forecast
Average Price Target
$51.50
▲(58.80% Upside)
Technical Analysis
Ownership Overview
3.07% Insiders
28.90% Mutual Funds
1.86% Other Institutional Investors
42.93% Public Companies and Individual Investors